KI-Beratung Beta

Gutscheinbedingungen

**Gültig am 20.11.2026 ab einem Mindestbestellwert von 30€ auf Spielzeug, Schreibwaren, Filme, Geschenke & Trends, Musik, tolino eReader & Zubehör, Hörbücher und Hörbuch-Downloads, nicht preisgebundene Bücher und Kalender online auf thalia.at und in der Thalia App. Einzelne Artikel können ausgeschlossen sein. Aufgrund der Buchpreisbindung sind deutschsprachige Bücher und eBooks ausgenommen. Zusätzlich ausgenommen sind Abos & Flatrates, Games, Geschenkkarten/-boxen, Shelfies, Software, Zeitschriften sowie einzelne Artikel von tonies®. Pro Einkauf einmal einlösbar. Click & Collect nur bei Onlinevorabzahlung möglich. Keine Barauszahlung. Nicht kombinierbar mit anderen Aktionen und Gutscheinen. Gutschein wird auf max. 500€ Bestellwert angerechnet. Nicht gültig für Versandkosten und Services. Preisgebundene Artikel sind vom Mindestbestellwert ausgeschlossen.

Beschreibung

The Progress in Medicinal Chemistry series spans a wide range of topics of interest to the drug discovery community. This particular volume touches upon the following: * The Herg ion channel * Fluorescence-based high throughput assay * Aprepitant and neurokinin receptors * Muscarinic receptor targets...

Beschreibung

The Progress in Medicinal Chemistry series spans a wide range of topics of interest to the drug discovery community. This particular volume touches upon the following:
* The Herg ion channel
* Fluorescence-based high throughput assay
* Aprepitant and neurokinin receptors
* Muscarinic receptor targets
* Gene activation pathways
* Malaria and antimalarial drugs
* HIV virus mutation and new therapeutics
Progress in Medicinal Chemistry is available online on ScienceDirect - full-text online of volumes 41 onwards.
Elsevier book series on ScienceDirect gives multiple users throughout an institution simultaneous online access to an important compliment to primary research. Digital delivery ensures users reliable, 24-hour access to the latest peer-reviewed content. The Elsevier book series are compiled and written by the most highly regarded authors in their fields and are selected from across the globe using Elsevier's extensive researcher network.
For more information about the Elsevier Book Series on ScienceDirect Program, please visit:

Rezension

Praise for the Series:
"...may the Progress in Medicinal Chemistry series continue its invaluable service..." --Chemistry and Industry

"... a valuable source of reference" --British Medical Journal

"...These volumes should be on the shelves of all specialist libraries which claim to cater for chemists, biologists, doctors and pharmacists and should be available to everyone interested in the contemporary controversy about drugs, drug firms and the community." --Pharmaceutical Journal

"...the consistently high standards for this series have been maintained in the present volume. This volume should certainly take its place next to the previous volumes in this series in libraries devoted to medicinal chemistry and drug research..." --Journal of Medicinal Chemistry

Portrait

Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.

From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines.

Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities.

Geoff serves on the Board of Antabio, a French biotech company developing tomorrow's antibacterial drugs.

He is a founder of INMedD, a new medicines discovery social enterprise.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

16.04.2005

Herausgeber F. D. King + weitere
Verlag Elsevier Science & Technology

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

16.04.2005

Herausgeber
Verlag Elsevier Science & Technology
Seitenzahl

302

Maße (L/B/H)

21/13,9/20,9 cm

Gewicht

510 g

Sprache

Englisch

ISBN

978-0-444-51572-8

EU-Ansprechpartner

Elsevier B.V.
Radarweg 29
1043 NX Amsterdam
NL
productsafety@elsevier.com

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Weitere Artikel finden Sie in

  • Produktbild: Progress in Medicinal Chemistry
  • Preface
    1. Human Ether-a-go-go Related Gene (Herg): A Chemist's Perspective
    2. Fluorescence Based Assays
    3. Selective and Combined Neurokinin Receptor Antagonists
    4. Muscarinic Receptor Subtype Pharmacology and Physiology
    5. The Transcription Factor NF-êB as Drug Target
    6. Recent Advances in the Search for New Antimarial Agents
    7. The Discovery of the CCR5 Receptor Antagonist UK-427857. A new agent for the Treatment of HIV infection and AIDS